Phaseline

Companies › Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MK-4002 (HPN217)
Bispecific antibody targeting BCMA and CD3
BCMA, CD3EPhase 1Multiple Myeloma in RelapseDec 2026
Gocatamig (HPN328, MK-6070)
DLL3-targeted trispecific antibody
DLL3Phase 1Small-Cell Lung CancerJan 2028
Ifinatamab Deruxtecan (I-DXd, DS-7300a, MK-2400)
Anti-CEACAM5 antibody-drug conjugate
CEACAM5Phase 1Small-Cell Lung CancerJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04184050MK-4002 (HPN217)Phase 1Multiple Myeloma in RelapseOncologyDec 2026
NCT04471727Gocatamig (HPN328, MK-6070)Phase 1Small-Cell Lung CancerOncologyJan 2028
NCT04471727Ifinatamab Deruxtecan (I-DXd, DS-7300a, MK-2400)Phase 1Small-Cell Lung CancerOncologyJan 2028

Targets

BCMA (1) CD3E (1) DLL3 (1) CEACAM5 (1)

Companies with the same targets

Johnson & Johnson (Janssen) AbbVie Roche Chongqing Precision Biotech Regeneron Pharmaceuticals AstraZeneca Amgen Novartis Beijing Biotech iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.